Could a malaria drug help fight recurrent bone cancer?
NCT ID NCT03598595
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding hydroxychloroquine (a malaria drug) to two chemotherapy drugs (gemcitabine and docetaxel) can help control osteosarcoma that has returned or stopped responding to treatment. About 31 participants will receive the combination to find the safest dose and see if it stops tumor growth. The goal is disease control, not a cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydroxychloroquine combined with gemcitabine and docetaxel
What this could lead to
If it works, this could offer a new treatment option for patients whose osteosarcoma has returned or stopped responding to standard therapy.
What could go wrong
This is an early-phase trial with only 31 participants, so results may not apply broadly. The combination may cause significant side effects or fail to control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States